Christopher Bredeson
Overview
Explore the profile of Christopher Bredeson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
2766
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Villeneuve P, Bredeson C
Curr Oncol
. 2023 May;
30(4):4033-4040.
PMID: 37185418
New therapies in a publicly funded healthcare system are first appraised by health technology assessment agencies that provide funding recommendations to the payers. Treatment with Chimeric Antigen Receptor-T cell (CAR-T)...
12.
Tamari R, McLornan D, Ahn K, Estrada-Merly N, Hernandez-Boluda J, Giralt S, et al.
Blood Adv
. 2023 May;
7(15):3993-4002.
PMID: 37134306
To develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients undergoing allo-HCT between 2000 and 2016 in...
13.
Kirkham A, Bailey A, Masurekar A, Shorr R, Bredeson C, Sabloff M, et al.
Leuk Lymphoma
. 2022 Sep;
63(14):3276-3287.
PMID: 36098248
Donor lymphocyte infusions (DLI) can produce graft-versus tumor effects to treat relapse after allogeneic hematopoietic cell transplantation, however, durable responses remain uncommon. A systematic review and meta-analysis are needed to...
14.
Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, et al.
Haematologica
. 2022 Apr;
108(1):150-160.
PMID: 35443559
Somatic mutations are recognized as an important prognostic factor in chronic myelomonocytic leukemia (CMML). However, limited data are available regarding their impact on outcomes after allogeneic hematopoietic cell transplantation (HCT)....
15.
Bailey A, Kirkham A, Monaghan M, Shorr R, Buchan C, Bredeson C, et al.
Curr Oncol
. 2022 Jan;
29(1):337-349.
PMID: 35049704
The management of COVID-19 in hematopoietic cell transplant (HCT) recipients represents a special challenge given the variable states of immune dysregulation and altered vaccine efficacy in this population. A systematic...
16.
Halpenny M, William N, Elmoazzen H, Giulivi A, Martin L, Perron D, et al.
Cytotherapy
. 2021 Oct;
24(3):223-224.
PMID: 34688545
No abstract available.
17.
Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang M, Bo-Subait K, Sanchez J, et al.
Blood Adv
. 2021 Sep;
6(3):828-847.
PMID: 34551064
Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the...
18.
Wieduwilt M, Metheny L, Zhang M, Wang H, Estrada-Merly N, Marks D, et al.
Blood Adv
. 2021 Sep;
6(1):339-357.
PMID: 34547770
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT...
19.
Oran B, Ahn K, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, et al.
Transplant Cell Ther
. 2021 Aug;
27(11):921.e1-921.e10.
PMID: 34403791
Reduced-intensity conditioning (RIC) regimens developed to extend the use of allogeneic hematopoietic stem cell transplantation (HSCT) to older patients have resulted in encouraging outcomes. We aimed to compare the 2...
20.
Chruscinski A, Juvet S, Moshkelgosha S, Renner E, Lilly L, Selzner N, et al.
Transplantation
. 2021 May;
106(3):562-574.
PMID: 34049362
Background: Primary sclerosing cholangitis (PSC) is an indication for liver transplantation, but recurrence after liver transplantation is associated with poor outcomes often requiring repeat transplantation. We investigated whether autologous hematopoietic...